Chronic Obstructive Pulmonary Disease Clinical Trial
— DETECTOfficial title:
Non-interventional Study for Documentation of the Therapeutic Efficacy, Use and Tolerance of the Fixed-Dose Combinations (FDC) Duaklir® Genuair® (Aclidinium/Formoterol), Ultibro® Breezhaler® (Glycopyrronium/Indacaterol) and Anoro® (Umeclidinium/Vilanterol) in the Treatment of COPD Under Real Conditions in the Practices of Pneumologists, Internists, and General Practitioners
| Verified date | December 2018 |
| Source | AstraZeneca |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational [Patient Registry] |
Prospective, multi-centre, non-interventional study to collect findings about the effects of LABA/LAMA (Long Acting Beta2-Agonists / Long Acting Muscarinic Antagonists) combination preparations on COPD (Chronic obstructive pulmonary disease) symptoms and quality of life under real conditions and to find out what types of patients are selected for this therapy by physicians.
| Status | Completed |
| Enrollment | 3732 |
| Est. completion date | December 31, 2017 |
| Est. primary completion date | December 31, 2017 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 40 Years and older |
| Eligibility |
Inclusion Criteria: - Female/male of at least 40 years of age - Patient diagnosed with COPD - Patient was changed over within the last 3 months to a fixed-dose combination (FDC) (Aclidinium/Formeterol, Glycopyrronium/Indacaterol or Umeclidinium/Vilanterol), or there is already the intent to change the patient over to a fixed-dose combination (Aclidinium/Formeterol, Glycopyrronium/Indacaterol or Umeclidinium/Vilanterol). - Lung function parameters and CAT score from the time prior to the changeover to an FDC are on record (within the last 6 months in the case of patients who have already been changed over) or are determined at the 1st visit (in the case of patients who have not yet been changed over but for whom such a changeover is intended). - Signed declaration of consent Exclusion Criteria: - The prescribing information for the fixed-dose combinations (Duaklir® Genuair®, Ulibtro® Breezhaler® or Anoro®) list contraindications for the patient. - Patient is pregnant, plans to become pregnant, or is nursing during the therapy period. - Patient suffers from hypersensitivity to one of the active ingredients of the fixed-dose combinations. - Patient is participating in a clinical trial. |
| Country | Name | City | State |
|---|---|---|---|
| Germany | Research Site | Aachen | D6570r00001 |
| Germany | Research Site | Aldenhofen | D6570r00001 |
| Germany | Research Site | Aldenhoven | D6570r00001 |
| Germany | Research Site | Alzey | D6570r00001 |
| Germany | Research Site | Ansbach | D6570r00001 |
| Germany | Research Site | Apolda | D6570r00001 |
| Germany | Research Site | Aschau | D6570r00001 |
| Germany | Research Site | Auerbach | D6570r00001 |
| Germany | Research Site | Augsburg | D6570r00001 |
| Germany | Research Site | Bad Fallingbostel | D6570r00001 |
| Germany | Research Site | Bad Hersfeld | D6570r00001 |
| Germany | Research Site | Bad Honnef | D6570r00001 |
| Germany | Research Site | Bad Lippspringe | D6570r00001 |
| Germany | Research Site | Bad Reichenhall | D6570r00001 |
| Germany | Research Site | Bad Sachsa | D6570r00001 |
| Germany | Research Site | Bad Windsheim | D6570r00001 |
| Germany | Research Site | Bad Woerishofen | D6570r00001 |
| Germany | Research Site | Bamberg | D6570r00001 |
| Germany | Research Site | Beelitz-Heilstaetten | D6570r00001 |
| Germany | Research Site | Bergisch Gladbach | D6570r00001 |
| Germany | Research Site | Berlin | D6570r00001 |
| Germany | Research Site | Biberach | D6570r00001 |
| Germany | Research Site | Birkenwerder | D6570r00001 |
| Germany | Research Site | Bitterfeld-Wolfen | D6570r00001 |
| Germany | Research Site | Bochum | D6570r00001 |
| Germany | Research Site | Boehlen | D6570r00001 |
| Germany | Research Site | Bonn | D6570r00001 |
| Germany | Research Site | Bottrop | D6570r00001 |
| Germany | Research Site | Braunschweig | D6570r00001 |
| Germany | Research Site | Bruchsal | D6570r00001 |
| Germany | Research Site | Buechen | D6570r00001 |
| Germany | Research Site | Burghaslach | D6570r00001 |
| Germany | Research Site | Burgwedel | D6570r00001 |
| Germany | Research Site | Celle | D6570r00001 |
| Germany | Research Site | Chemnitz | D6570r00001 |
| Germany | Research Site | Cottbus | D6570r00001 |
| Germany | Research Site | Darmstadt | D6570r00001 |
| Germany | Research Site | Delitzsch | D6570r00001 |
| Germany | Research Site | Dessau | D6570r00001 |
| Germany | Research Site | Dorsten | D6570r00001 |
| Germany | Research Site | Dortmund | D6570r00001 |
| Germany | Research Site | Dresden | D6570r00001 |
| Germany | Research Site | Dueren | D6570r00001 |
| Germany | Research Site | Duesseldorf | D6570r00001 |
| Germany | Research Site | Duisburg | D6570r00001 |
| Germany | Research Site | Eimsheim | D6570r00001 |
| Germany | Research Site | Ellerstadt | D6570r00001 |
| Germany | Research Site | Elsterwerda | D6570r00001 |
| Germany | Research Site | Elterlein | D6570r00001 |
| Germany | Research Site | Essen | D6570r00001 |
| Germany | Research Site | Euerbach-Obbach | D6570r00001 |
| Germany | Research Site | Euskirchen | D6570r00001 |
| Germany | Research Site | Flensburg | D6570r00001 |
| Germany | Research Site | Frankfurt | D6570r00001 |
| Germany | Research Site | Frankfurt/M. | D6570r00001 |
| Germany | Research Site | Freiberg | D6570r00001 |
| Germany | Research Site | Fuerstenwalde | D6570r00001 |
| Germany | Research Site | Fuerth | D6570r00001 |
| Germany | Research Site | Ganderkesee | D6570r00001 |
| Germany | Research Site | Garching | D6570r00001 |
| Germany | Research Site | Garmisch-Partenkirchen | D6570r00001 |
| Germany | Research Site | Gauting | D6570r00001 |
| Germany | Research Site | Gera | D6570r00001 |
| Germany | Research Site | Gerwisch | D6570r00001 |
| Germany | Research Site | Glienicke | D6570r00001 |
| Germany | Research Site | Greiz | D6570r00001 |
| Germany | Research Site | Guetersloh | D6570r00001 |
| Germany | Research Site | Hagen | D6570r00001 |
| Germany | Research Site | Halberstadt | D6570r00001 |
| Germany | Research Site | Halle | D6570r00001 |
| Germany | Research Site | Hamburg | D6570r00001 |
| Germany | Research Site | Hannover | D6570r00001 |
| Germany | Research Site | Hartenstein | D6570r00001 |
| Germany | Research Site | Heidelberg | D6570r00001 |
| Germany | Research Site | Hemmingen | D6570r00001 |
| Germany | Research Site | Hettstedt | D6570r00001 |
| Germany | Research Site | Hoechstadt | D6570r00001 |
| Germany | Research Site | Hoyerswerda | D6570r00001 |
| Germany | Research Site | Ibbenbueren | D6570r00001 |
| Germany | Research Site | Ingolstadt | D6570r00001 |
| Germany | Research Site | Iserlohn | D6570r00001 |
| Germany | Research Site | Issum | D6570r00001 |
| Germany | Research Site | Jena | D6570r00001 |
| Germany | Research Site | Karlsruhe | D6570r00001 |
| Germany | Research Site | Kevelaer | D6570r00001 |
| Germany | Research Site | Kleve | D6570r00001 |
| Germany | Research Site | Koeln | D6570r00001 |
| Germany | Research Site | Koeln-Hoehenberg | D6570r00001 |
| Germany | Research Site | Koeln-Rodenkirchen | D6570r00001 |
| Germany | Research Site | Koethen | D6570r00001 |
| Germany | Research Site | Kolbermoor | D6570r00001 |
| Germany | Research Site | Krefeld | D6570r00001 |
| Germany | Research Site | Kronach | D6570r00001 |
| Germany | Research Site | Kyritz | D6570r00001 |
| Germany | Research Site | Langenfeld | D6570r00001 |
| Germany | Research Site | Leer | D6570r00001 |
| Germany | Research Site | Leipzig | D6570r00001 |
| Germany | Research Site | Leonberg | D6570r00001 |
| Germany | Research Site | Lippstadt | D6570r00001 |
| Germany | Research Site | Ludwigsburg-Ossweil | D6570r00001 |
| Germany | Research Site | Ludwigshafen | D6570r00001 |
| Germany | Research Site | Luebeck | D6570r00001 |
| Germany | Research Site | Magdeburg | D6570r00001 |
| Germany | Research Site | Mainz | D6570r00001 |
| Germany | Research Site | Mannheim | D6570r00001 |
| Germany | Research Site | Marburg | D6570r00001 |
| Germany | Research Site | Markt Bibart | D6570r00001 |
| Germany | Research Site | Menden | D6570r00001 |
| Germany | Research Site | Merzig | D6570r00001 |
| Germany | Research Site | Moenchengladbach | D6570r00001 |
| Germany | Research Site | Moers | D6570r00001 |
| Germany | Research Site | Monheim | D6570r00001 |
| Germany | Research Site | Mosbach | D6570r00001 |
| Germany | Research Site | Muehlhausen | D6570r00001 |
| Germany | Research Site | Muenchen | D6570r00001 |
| Germany | Research Site | Neumarkt | D6570r00001 |
| Germany | Research Site | Neunkirchen | D6570r00001 |
| Germany | Research Site | Neuruppin | D6570r00001 |
| Germany | Research Site | Neusaess | D6570r00001 |
| Germany | Research Site | Neustadt/Aisch | D6570r00001 |
| Germany | Research Site | Neuwied | D6570r00001 |
| Germany | Research Site | Nuernberg | D6570r00001 |
| Germany | Research Site | Oettingen | D6570r00001 |
| Germany | Research Site | Oschatz | D6570r00001 |
| Germany | Research Site | Oy-Mittelberg | D6570r00001 |
| Germany | Research Site | Pirmasens | D6570r00001 |
| Germany | Research Site | Potsdam | D6570r00001 |
| Germany | Research Site | Pulheim-Braunweiler | D6570r00001 |
| Germany | Research Site | Radebeul | D6570r00001 |
| Germany | Research Site | Rastatt | D6570r00001 |
| Germany | Research Site | Rathenow | D6570r00001 |
| Germany | Research Site | Recklinghausen | D6570r00001 |
| Germany | Research Site | Remscheid | D6570r00001 |
| Germany | Research Site | Reutlingen | D6570r00001 |
| Germany | Research Site | Rosenheim | D6570r00001 |
| Germany | Research Site | Rostock | D6570r00001 |
| Germany | Research Site | Roth | D6570r00001 |
| Germany | Research Site | Ruedersdorf | D6570r00001 |
| Germany | Research Site | Ruesselsheim | D6570r00001 |
| Germany | Research Site | Rust | D6570r00001 |
| Germany | Research Site | Saalfeld | D6570r00001 |
| Germany | Research Site | Saarbruecken | D6570r00001 |
| Germany | Research Site | Saarlouis | D6570r00001 |
| Germany | Research Site | Schleswig | D6570r00001 |
| Germany | Research Site | Schmoelln | D6570r00001 |
| Germany | Research Site | Schoenbrunn | D6570r00001 |
| Germany | Research Site | Schwedt | D6570r00001 |
| Germany | Research Site | Siegen | D6570r00001 |
| Germany | Research Site | Simmern | D6570r00001 |
| Germany | Research Site | Solingen | D6570r00001 |
| Germany | Research Site | Sonsbeck | D6570r00001 |
| Germany | Research Site | Spiesen | D6570r00001 |
| Germany | Research Site | Spremberg | D6570r00001 |
| Germany | Research Site | Steinhagen | D6570r00001 |
| Germany | Research Site | Strasskirchen | D6570r00001 |
| Germany | Research Site | Strausberg | D6570r00001 |
| Germany | Research Site | Stuttgart | D6570r00001 |
| Germany | Research Site | Sulzberg | D6570r00001 |
| Germany | Research Site | Teterow | D6570r00001 |
| Germany | Research Site | Teuchern | D6570r00001 |
| Germany | Research Site | Thaleischweiler-Froeschen | D6570r00001 |
| Germany | Research Site | Trier | D6570r00001 |
| Germany | Research Site | Ulm | D6570r00001 |
| Germany | Research Site | Unterwellenborn | D6570r00001 |
| Germany | Research Site | Ursensollen | D6570r00001 |
| Germany | Research Site | Voerde | D6570r00001 |
| Germany | Research Site | Wallenhorst | D6570r00001 |
| Germany | Research Site | Wardenburg | D6570r00001 |
| Germany | Research Site | Waren | D6570r00001 |
| Germany | Research Site | Warendorf | D6570r00001 |
| Germany | Research Site | Wehrheim | D6570r00001 |
| Germany | Research Site | Weilheim | D6570r00001 |
| Germany | Research Site | Weissenburg | D6570r00001 |
| Germany | Research Site | Weisswasser | D6570r00001 |
| Germany | Research Site | Wiesbaden | D6570r00001 |
| Germany | Research Site | Witten | D6570r00001 |
| Germany | Research Site | Wittenberg | D6570r00001 |
| Germany | Research Site | Worms | D6570r00001 |
| Germany | Research Site | Wuppertal | D6570r00001 |
| Germany | Research Site | Zwoenitz | D6570r00001 |
| Lead Sponsor | Collaborator |
|---|---|
| AstraZeneca |
Germany,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Lung function | Assessment of FEV1 (Forced Expiratory Volume), FVC (Forced Vital Capacity) | First visit (baseline) | |
| Primary | Number of patients with concomitant diseases classified by diagnostic subgroups | First visit (baseline) | ||
| Primary | Number of patients receiving concomitant COPD (Chronic obstructive pulmonary disease) medication classified by therapeutic subgroups | First visit (baseline) | ||
| Primary | Number of patients with exacerbations within the previous 24 months | History of previous exacerbations that will be collected at first observational visit. | First visit (baseline) | |
| Secondary | Change in well-being and quality of life | CAT (COPD Assessment Test™) questionnaire will be completed at each visit, approximately every 3 months. | First visit (baseline) to end of observational period at 12 months | |
| Secondary | Effect on the severity of the shortness of breath | mMRC (modified Medical Research Council Dyspnea Scale) questionnaire will be completed at each visit, approximately every 3 months. | First visit (baseline) to end of observational period at 12 months | |
| Secondary | Change in the night-time and early-morning COPD symptoms | NiSCI/EMSCI (Night-time symptoms of COPD Instrument / Early-morning symptoms of COPD instrument) questionnaire will be completed at each visit, approximately every 3 months. | First visit (baseline) to end of observational period at 12 months | |
| Secondary | Lung function | Assessment of FEV1, FVC at each visit, approximately every 3 months. | First visit (baseline) to end of observational period at 12 months | |
| Secondary | Number of exacerbations by grade | Number of exacerbations will be collected at each visit, approximately every 3 months | First visit (baseline) to end of observational period at 12 months | |
| Secondary | Adverse events | Adverse events will be collected at each visit, approximately every 3 months. | First visit (baseline) to end of observational period at 12 months | |
| Secondary | Handling of inhaler | Questionnaire regarding handling of inhaler by patient | At 12 months |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05102305 -
A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
|
||
| Completed |
NCT01867762 -
An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
| Recruiting |
NCT05562037 -
Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA
|
N/A | |
| Terminated |
NCT04921332 -
Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD
|
N/A | |
| Completed |
NCT03089515 -
Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust
|
N/A | |
| Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
| Recruiting |
NCT05552833 -
Pulmonary Adaptive Responses to HIIT in COPD
|
N/A | |
| Recruiting |
NCT05835492 -
A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
|
||
| Recruiting |
NCT05631132 -
May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases?
|
N/A | |
| Completed |
NCT03244137 -
Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
|
||
| Not yet recruiting |
NCT03282526 -
Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease
|
N/A | |
| Completed |
NCT02546700 -
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 2 | |
| Withdrawn |
NCT04446637 -
Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD
|
Phase 3 | |
| Completed |
NCT04535986 -
A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
|
Phase 3 | |
| Recruiting |
NCT05865184 -
Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
|
||
| Completed |
NCT03295474 -
Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
|
||
| Completed |
NCT03256695 -
Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
| Withdrawn |
NCT04042168 -
Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
| Completed |
NCT03414541 -
Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
| Recruiting |
NCT05306743 -
PRagmatic EVAluation of a Quality Improvement Program for People Living With Modifiable High-risk COPD.
|
N/A |